Clinical feature no. %
Patients 200  
Healthy Controls 25  
Gender
Males 128 64.0%
Female 72 36.0%
Age
Age >45 71 35.5%
Age <45 129 64.5%
BCR-ABL transcripts
a2b2 59 29.5%
a2b3 124 62.0%
a2b2/ a2b3 17 8.5%
Staging of the disease    
Chronic phase-CML 81 40.5%
Accelerated phase-CML 54 27.0%
Blast crisis-CML 65 32.5%
Molecular Response
Major molecular response(MMR) 50 25.0%
No molecular response 150 75.0%
Haematological responses
Major haematological response(MHR) 30 15.0%
Minor haematological response(mHR) 46 23.0%
No haematological response 124 77.0%
Type of therapy
Imatinib treated 200 100%
Dasatinib treated (Imatinib failure) 10 5.0%
Thrombocytopenia
Thrombocytopenia 100 50.0%
No Thrombocytopenia 100 50.0%
Table4: Demographic classification in CML patients.